ASH 2023 | Outcomes of patients with Richter’s transformation without prior chemoimmunotherapy for CLL/SLL
Adam Kittai, MD, Ohio State University, Columbus, OH, comments on a multicenter retrospective study which investigated the variables predictive of survival in Richter’s transformation patients who did not undergo prior chemoimmunotherapy (CIT) for their chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and have been treated exclusively with small molecule inhibitors (SMI) (BTK and BCL2 inhibitors). Those patients who did not undergo any treatment for CLL/SLL prior to RT (both CIT and/or SMI), had greater disease outcomes than those who were treated for their CLL/SLL, highlighting the need to improve treatment of patients who are not treatment naïve at the time of transformation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, AstraZeneca, AbbVie, Janssen, KITE, BMS
Research Funding,: BeiGene, AstraZeneca
Speakers Bureau: BeiGene
